Short Summary
The PTAB issued a final decision finding the challenged claims unpatentable over Xu-752 and Jones. The Board concluded that the Petitioner failed to demonstrate non-hindsight motivation for combining the references or making the necessary technical modifications, citing lack of support for millisecond time resolution.
Detailed Summary
In this Final Written Decision, the Patent Owner (Agilent Technologies, Inc.) prevailed against the Petitioner (Axion Biosystems, Inc.), asserting that the claims were obvious over Xu-752 and Jones under 35 U.S.C. § 103. The Board rejected the argument that a Person of Ordinary Skill in the Art would combine these references to achieve millisecond time resolution. Specifically, the Board found insufficient evidence to support the Petitioner's modifications, noting that Jones only exemplified a 1.5-second period and that the proposed technical selections required hindsight bias.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Axion Biosystems, Inc. vs Agilent Technologies, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
TROVE BRANDS, LLCvsCamelBak Products, LLC
Trove Brands has filed an IPR petition seeking to invalidate CamelBak's 10,165,879 patent covering removable cap assemblies for drink containers, alleging obviousness over multiple prior‑art references and arguing against discretionary denial.
Samsung Electronics America, Inc. et al.vsKoninklijke KPN N.V.
Samsung and Dutch telecom firm KPN have reached a confidential settlement and jointly moved to terminate the IPR concerning patent 9,462,544. The Board is asked to dismiss the proceeding under 35 U.S.C. § 317(a).
Sarepta Therapeutics, Inc. et al.vsGenzyme Corporation et al.
Sarepta Therapeutics has filed an IPR petition seeking cancellation of claims 1‑20 of Genzyme’s ‘377 patent on AAV detection methods, arguing the claims are obvious over four prior‑art references. The petition details three grounds of obviousness and asserts no secondary considerations outweigh the evidence.
Imperative Care, Inc.vsInari Medical, Inc.
The PTAB has instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All challenged claims (1‑8, 12‑19) are now subject to trial.
Google LLCvsSecure Communication Technologies, LLC
Google’s IPR against a proximity‑based advertising patent resulted in five of the nine challenged claims being found unpatentable, while the remaining four claims were upheld.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.